Expression of PD-L1 correlates with pleomorphic morphology and histological patterns of non-small-cell lung carcinomas

Pulmonary Sarcomatoid Carcinomas Commonly Harbor Either Potentially Targetable Genomic Alterations or High Tumor Mutational Burden as Observed by Comprehensive Genomic Profiling

(2017) Alexa B. Schrock et al.   Journal of Thoracic Oncology

PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project

(2017) Fred R. Hirsch et al.   Journal of Thoracic Oncology

First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer

(2017) David P. Carbone et al.   NEW ENGLAND JOURNAL OF MEDICINE

Paired Comparison of PD-L1 Expression on Cytologic and Histologic Specimens From Malignancies in the Lung Assessed With PD-L1 IHC 28-8pharmDx and PD-L1 IHC 22C3pharmDx

(2017) Birgit G. Skov et al.   APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY

A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non–Small Cell Lung Cancer

(2017) David L. Rimm et al.   JAMA Oncology

Characteristics and Prognostic Analysis of 69 Patients With Pulmonary Sarcomatoid Carcinoma

(2016) Yongbin Lin et al.   AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

Minor Components of Micropapillary and Solid Subtypes in Lung Adenocarcinoma are Predictors of Lymph Node Metastasis and Poor Prognosis

(2016) Yue Zhao et al.   ANNALS OF SURGICAL ONCOLOGY

Prognostic Role of Subtype Classification in Small-Sized Pathologic N0 Invasive Lung Adenocarcinoma

(2016) Tomoharu Yoshiya et al.   ANNALS OF THORACIC SURGERY

PD-L1 testing for lung cancer in the UK: recognizing the challenges for implementation

(2016) Ian A Cree et al.   HISTOPATHOLOGY

Next-Generation Sequencing of Pulmonary Sarcomatoid Carcinoma Reveals High Frequency of Actionable MET Gene Mutations

(2016) Xuewen Liu et al.   JOURNAL OF CLINICAL ONCOLOGY

The IASLC Lung Cancer Staging Project: Proposals for Coding T Categories for Subsolid Nodules and Assessment of Tumor Size in Part-Solid Tumors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer

(2016) William D. Travis et al.   Journal of Thoracic Oncology

Programmed Cell Death Ligand 1 Expression in Resected Lung Adenocarcinomas: Association with Immune Microenvironment

(2016) Tiffany G. Huynh et al.   Journal of Thoracic Oncology

The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer

(2016) Peter Goldstraw et al.   Journal of Thoracic Oncology

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

(2016) Jonathan E Rosenberg et al.   LANCET

Aggressive tumor microenvironment of solid predominant lung adenocarcinoma subtype harboring with epidermal growth factor receptor mutations

(2016) Koichi Saruwatari et al.   LUNG CANCER

Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas

(2016) Andreas H Scheel et al.   MODERN PATHOLOGY

Expression of PD-L1 Identifies a Subgroup of More Aggressive Non-Small Cell Carcinomas of the Lung

(2016) William Sterlacci et al.   PATHOBIOLOGY

Checkpoint inhibitors in lung cancer: latest developments and clinical potential

(2016) Gustavo Schvartsman et al.   Therapeutic Advances in Medical Oncology

Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib

(2015) J. F. Gainor et al.   CLINICAL CANCER RESEARCH

Subtype Classification of Lung Adenocarcinoma Predicts Benefit From Adjuvant Chemotherapy in Patients Undergoing Complete Resection

(2015) Ming-Sound Tsao et al.   JOURNAL OF CLINICAL ONCOLOGY

Programmed Death-Ligand 1 Immunohistochemistry in Lung Cancer: In what state is this art?

(2015) Keith M. Kerr et al.   Journal of Thoracic Oncology

Clinicopathologic analysis of programmed cell death-1 and programmed cell death-ligand 1 and 2 expressions in pulmonary adenocarcinoma: comparison with histology and driver oncogenic alteration status

(2015) Jaemoon Koh et al.   MODERN PATHOLOGY

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

(2015) Edward B. Garon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

(2015) Julie Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

(2015) N. A. Rizvi et al.   SCIENCE

Predictive Value of the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Classification of Lung Adenocarcinoma in Tumor Recurrence and Patient Survival

(2014) Jung-Jyh Hung et al.   JOURNAL OF CLINICAL ONCOLOGY

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

(2014) Roy S. Herbst et al.   NATURE

Impact of EGFR Inhibitor in Non–Small Cell Lung Cancer on Progression-Free and Overall Survival: A Meta-Analysis

(2013) Chee Khoon Lee et al.   JNCI-Journal of the National Cancer Institute

Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2012) S. Peters et al.   ANNALS OF ONCOLOGY

Cancer statistics, 2012

(2012) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

The Value of Biomarkers in Patients With Sarcomatoid Carcinoma of the Lung: Molecular Analysis of 33 Cases

(2012) Xiangli Jiang et al.   Clinical Lung Cancer

The Novel Histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Classification System of Lung Adenocarcinoma Is a Stage-Independent Predictor of Survival

(2012) Arne Warth et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognostic Significance of Predominant Histologic Pattern and Nuclear Grade in Resected Adenocarcinoma of the Lung: Potential Parameters for a Grading System

(2012) Jan H. von der Thüsen et al.   Journal of Thoracic Oncology

Validation of the IASLC/ATS/ERS Lung Adenocarcinoma Classification for Prognosis and Association with EGFR and KRAS Gene Mutations: Analysis of 440 Japanese Patients

(2012) Akihiko Yoshizawa et al.   Journal of Thoracic Oncology

Adenocarcinomas With Prominent Lepidic Spread

(2011) Lauren Xu et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Global cancer statistics

(2011) Ahmedin Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Does Lung Adenocarcinoma Subtype Predict Patient Survival?: A Clinicopathologic Study Based on the New International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Lung Adenocarcinoma Classification

(2011) Prudence A. Russell et al.   Journal of Thoracic Oncology

A Grading System of Lung Adenocarcinomas Based on Histologic Pattern is Predictive of Disease Recurrence in Stage I Tumors

(2010) Gabriel Sica et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

EGFR and KRAS status of primary sarcomatoid carcinomas of the lung: Implications for anti-EGFR treatment of a rare lung malignancy

(2009) Antoine Italiano et al.   INTERNATIONAL JOURNAL OF CANCER

Pleomorphic Carcinoma of the Lung

(2008) Takahiro Mochizuki et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY